HERTFORDSHIRE, England and PITTSBURGH, Oct. 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) provided the following statement in response to the announcement of proposed amendments to the civil complaint by various states' attorneys general in multi-district litigation pending in the U.S. District Court for the Eastern District of Pennsylvania against Mylan and 17 other pharmaceutical companies:
We have been investigating these allegations thoroughly and have found no evidence of price fixing on the part of Mylan or its employees. Our review of the Connecticut Attorney General's press release underpinning the complaint does not change our views. We have asked the various attorneys general leading this case to share with us what information they believe supports these new allegations and, to date, they have not done so. Mylan has deep faith in the integrity of its President, Rajiv Malik, and stands behind him fully. Mylan and Rajiv Malik both intend to defend this case vigorously, and we look forward to the opportunity to present a full defense.
Mylan takes its legal obligations seriously and operates with the highest levels of integrity and character. Mylan expects to have no further comment while the matter is pending.
SOURCE Mylan N.V.